ClinicalTrials.gg
CompletedNCT04892641Updated Mar 21, 2024

Phase 1 Study of Epetraborole Tablets

A Phase 1 interventional study of Epetraborole and Placebo in Healthy Volunteers, sponsored by AN2 Therapeutics, Inc. Completed at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-21.

Sponsored by AN2 Therapeutics, Inc · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Feb 2022, 4 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a Phase 1b double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, PK, and food effect of epetraborole tablets administered to healthy adult subjects for up to 28 days.

Read the detailed description

Up to 56 healthy male and female adult subjects will be enrolled into one of 7 Dose Cohorts (Dose Cohorts 1 to 7; n = 8 per cohort). Cohort 7 (n = 8) is a Food Effect Cohort and subjects will receive a single dose of epetraborole or placebo in a Fasted state (Period 1) followed by a second dose of the same Investigational Product (IP) in a Fed state (Period 2) after a washout period of at least 7 days (+3 days). The dose of IP to be administered in Cohort 7 will be determined based on the Safety Monitoring Group recommendation following evaluation of safety and available PK data (at least 14 days) in Cohort 1 through Cohort 6. Up to 16 additional subjects may be included for the purposes of cohort expansion or to explore a dose intermediate to previously evaluated doses.

Subjects in each Dose Cohort (n=8) will be randomized 3:1 to receive epetraborole (n=6) or matching placebo (n=2) and will receive oral doses of epetraborole or placebo. Investigational product will be administered with approximately 240 mL (8 fluid ounces) of non-carbonated water to each subject following an overnight fast of at least 8 hours, except for Period 2 (Fed) of Cohort 7. Subjects will be required to fast for a minimum of 2 hours following administration of IP.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

AN2 Therapeutics, Inc is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects who meet all the following criteria will be considered for inclusion in the study:

  1. Healthy adult males and/or females of 18 to 65 years of age (inclusive) at the time of Screening.
  2. Willing and able to provide written .
  3. (BMI) ≥ 18.0 and ≤ 30.0 kg/m2 and weight between 40.0 kg and 100.0 kg (inclusive) at Screening.
  4. Medically healthy without CS abnormalities at the Screening Visit or Day -1, including:

    1. Physical examination, vital signs including temperature, HR, respiratory rate, and blood pressure
    2. Triplicate ECGs taken at least 1 minute apart with interval duration ≤ 450 msec obtained as an average from the triplicate Screening and pre-dose Day 1 ECGs after at least 5 minutes in a semi-supine, quiet rest position
    3. Hematological parameters (including , hematocrit, red blood cells [RBC], packed cell volume [PCV], mean corpuscular volume [MCV], mean corpuscular hemoglobin [MCH], mean corpuscular hemoglobin concentration [MCHC], red cell distribution width [RDW], count, white blood cell [WBC] and differential, and reticulocytes) are equal to or greater than the lower limit of normal (LLN) of the normal range of the reference laboratory
    4. Estimated (CrCl) or (GFR) \< 80 mL/min using Cockcroft-Gault formula (calculated creatinine clearance or GFR = [{140-Age} × Weight {in kg}] \ [72 × Serum creatinine {in mg/dL}] × 0.85 [if female]); and AST equal to or ≤ 1.5 times the ; results of all other clinical chemistry and urine analytes without any CS abnormality Note: Discussion between the PI and the Sponsor Medical Monitor (MM) is required regarding any potentially CS abnormal laboratory value during the pre-dose period.
  5. Non-smoker (including tobacco, e-cigarettes, nicotine patches or marijuana) for at least 1 month prior to randomization, which will be confirmed by urine cotinine test at Screening and on Day -1 (admission).
  6. Willing and able to comply with all study assessments and adhere to the protocol schedule, including the entire confinement period and the F/U visits.
  7. Have suitable venous access for blood sampling.
  8. Women of (WOCBP) must have a negative pregnancy test at Screening and on Day -1 (admission) and be willing to have additional pregnancy tests, as required, throughout the study.

    WOCBP must agree to and comply with using 1 barrier method (e.g., female condom or male partner using a condom) plus 1 other highly effective method of (e.g., oral contraceptive pills [OCPs], long-acting implantable hormones, injectable hormones, intrauterine device [IUD], vasectomized partner), or sexual abstinence, for the duration of the study (from signing of consent to final F/U visit) and for 30 days after last IP administration.

    WOCBP must also agree not to donate ova or oocytes (i.e., human eggs) during the study, and for one menstrual cycle after completion of the study To be considered of non-childbearing potential, a female must have either a tubal ligation, hysterectomy, bilateral salpingo-oophrectomy, or menopause (last menstruation > 12 months and follicle-stimulating hormone [FSH] levels ≥ 40 IU/mL at Screening); provision of written documentation is not required for female sterilization and oral confirmation is adequate.

    Female subjects who are in same-sex relationships are not required to use contraception.

  9. Males must be surgically sterile (> 30 days since vasectomy), abstinent, or if engaged in sexual relations with a WOCBP, the subject and his partner must be surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or using an acceptable, highly effective contraceptive method from Screening until study completion, including the F/U period. Acceptable methods of contraception include the use of condoms and the use of an effective contraceptive for the female partner that includes: OCPs, long-acting implantable hormones, injectable hormones, a vaginal ring or an IUD. Subjects with same-sex partners are eligible when this is their preferred and usual lifestyle.

    Males must not donate sperm for the duration of the study (from signing of consent to final F/U visit) and for 90 days after last IP administration.

  10. Subjects must agree to adhere to the current state and national advice regarding minimizing exposure to coronavirus disease of 2019 (COVID-19) from the first Screening Visit until the final F/U visit.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating at Screening or planning to become pregnant (self or partner) at any time during the study, including the F/U period.
  2. History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological disease, including any acute illness or major surgery within the past 3 months determined by the PI to be CS.
  3. Iron, B12 or folate outside of the normal range at Screening and any history of anemia (e.g. iron deficiency, B12 or folate deficiency, or hemoglobinopathy).
  4. Lymphoma, leukemia, or any within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for 3 years prior to Screening.
  5. Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome).
  6. Has/had febrile illness or symptomatic viral, bacterial (including upper respiratory tract infection) or fungal infection within 2 weeks prior to randomization.
  7. Unable to swallow solid, oral dosage forms whole with the aid of water.
  8. Positive test for (HIV), surface antigen (HBsAg), and virus (HCV) antibody.
  9. Positive urine drug screen or alcohol breath test at Screening or Day -1, or history of substance abuse or alcohol abuse (defined as greater than 2 standard drinks on average each and every day, where 1 standard drink is defined as containing 10 g of alcohol and is equivalent to 1 can or stubby of mid-strength beer, 30 mL nip of spirits, or 100 mL of wine) within the previous 6 months.
  10. Use of any prescription medication or any over the counter (OTC) medication, including erythropoietin stimulating agents, herbal products and vitamins, within 7 days prior to randomization.

    Note: An exception is made for hormonal and intermittent, as-needed acetaminophen or nonsteroidal anti-inflammatory drugs (NSAIDs) for the treatment of transient headache or any other minor ache/pain. Discussion between the PI and the Sponsor MM is encouraged regarding the acceptability of the prior use of any medications during the pre-dose period.

  11. Any vaccinations or planned vaccinations (including COVID-19 and influenza) within 14 days prior to dosing on Day 1 and for the duration of the study (up to the F/U visit).
  12. Documented significant reaction or anaphylaxis to any medication, which in the opinion of the Investigator could compromise subject safety.
  13. Donation of blood or plasma within 30 days prior to randomization, or loss of whole blood of more than 500 mL within 30 days prior to randomization, or past receipt of a blood transfusion at any time.
  14. Received an intervention (including an investigational vaccine) or used an invasive investigational medical device within 30 days (or 5 half-lives whichever is longer) prior to Day 1.
  15. Any other condition or prior therapy, which, in the opinion of the PI, would make the volunteer unsuitable for this study, including unable to cooperate fully with the requirements of the study protocol or likely to be non-compliant with any study requirements.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Epetraborole for Dose Ranging

    Epetraborole hydrochloride 250 mg, 500 mg, 750 mg, or 1000 mg PO q24h or 500 mg or 1000 mg PO q48h

    Drug: Epetraborole

  • Placebo comparator
    Placebo for Dose Ranging

    Matching placebo for dose ranging

    Drug: Placebo

  • Experimental
    Epetraborole for Food Effect

    Food effect cohort, single dose in fed and fasted conditions, dosage to be determined based on pharmacokinetics data obtained from previous cohorts

    Drug: Epetraborole

  • Placebo comparator
    Placebo for Food Effect

    Food effect cohort, single dose in fed and fasted conditions, dosage to be determined based on pharmacokinetics data obtained from previous cohorts

    Drug: Placebo

Interventions

  • Epetraborole hydrochloride 250 mg tablets for oral administration

    Also known as: AN2-501971

  • DrugPlacebo

    Matching placebo for 250 mg epetraborole hydrochloride tablets for oral administration

06

What researchers measure

Primary outcomes

  1. Evaluate the Incidence of Treatment Emergent Adverse Events at Baseline and Through Study Completion

    Incidence, relatedness, and severity of adverse events

    Time frame: From Day 1 through last follow-up visit (7 days after last dose)

  2. Evaluate Physical Examination Abnormalities from Baseline Through Study Completion

    Incidence of physical exam abnormalities

    Time frame: From Day 1 through last follow-up visit (7 days after last dose)

  3. Evaluate Change in Vital Signs from Baseline Through Study Completion

    Incidence of changes in blood pressure, pulse, respiratory rate, and temperature

    Time frame: From Day 1 to follow-up visit through last follow-up visit (7 days after last dose)

  4. Evaluate Changes in 12-lead ECG Measurements from Baseline Through Study Completion

    Incidence of changes in 12-lead ECG parameters from baseline

    Time frame: From Day 1 to follow-up visit through last follow-up visit (7 days after last dose)

  5. Evaluate Changes in Clinical Laboratory Tests from Baseline Through Study Completion

    Incidence of changes in clinical laboratory measurements from baseline

    Time frame: From Day 1 to follow-up visit through last follow-up visit (7 days after last dose)

  6. Characterize the PK Profile of Epetraborole: Maximum Plasma Concentration

    Determination of the maximum plasma concentration (Cmax)

    Time frame: From Day 1 to follow-up visit through last follow-up visit (7 days after last dose)

  7. Characterize the PK Profile of Epetraborole: Minimum Steady State Plasma Concentration During a Dosage Interval

    Determination of the minimum steady state plasma drug concentration during a dosage interval (Cmin)

    Time frame: From Day 1 to follow-up visit through last follow-up visit (7 days after last dose)

  8. Characterize the PK Profile of Epetraborole: Time to Maximum Plasma Concentration

    Determination the time to maximum plasma concentration (Tmax)

    Time frame: From Day 1 to follow-up visit through last follow-up visit (7 days after last dose)

  9. Characterize the PK Profile of Epetraborole: Area Under the Plasma Concentration Versus Time Curve from Time 0 to the Last Time Point Evaluated

    Determine the area under the plasma concentration versus time curve from time 0 to the last time point evaluated (AUC0-t) with the plasma concentration at time "t" being the last measurable concentration

    Time frame: From Day 1 to follow-up visit through last follow-up visit (7 days after last dose)

  10. Characterize the PK Profile of Epetraborole: Area Under the Plasma Concentration Versus Time Curve from Time 0 to Infinity

    Determine area under the drug concentration versus time curve, from time zero to infinity (AUC0-inf)

    Time frame: From Day 1 to follow-up visit through last follow-up visit (7 days after last dose)

  11. Characterize the PK Profile of Epetraborole: Last Quantifiable Concentration

    Determine the actual time of last quantifiable concentration used in the determination of AUC0-last (Tlast)

    Time frame: From Day 1 to follow-up visit through last follow-up visit (7 days after last dose)

  12. Characterize the PK Profile of Epetraborole: Terminal Half-Life

    Determine the apparent terminal half-life (t½)

    Time frame: From Day 1 to follow-up visit through last follow-up visit (7 days after last dose)

  13. Characterize the PK Profile of Epetraborole: Terminal Elimination Rate Constant

    Determine apparent terminal elimination rate constant (Kel)

    Time frame: From Day 1 to follow-up visit through last follow-up visit (7 days after last dose)

07

Study locations

1 site
  • CMAX Clinical Research
    Adelaide, South Australia 5000, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Feb 2022, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2021
First posted
May 19, 2021
StartActual
Jun 10, 2021
Primary completionActual
Feb 26, 2022
CompletionActual
Feb 26, 2022
Last update
Mar 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04892641
Lead sponsor
AN2 Therapeutics, Inc
Responsible party
Sponsor
First posted
May 19, 2021
Start date
Jun 10, 2021
Primary completion
Feb 26, 2022
Completion
Feb 26, 2022
Last update
Mar 21, 2024

Study contacts

Angela Molga, M.D.
principal investigator · CMAX Clinical Research

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epetraborole

Start the discussion